ESPR FY 2019 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

FY 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$148M-19.6% YoY

Gross Profit

$148M100.0% margin

Operating Income

-$93M-62.8% margin

Net Income

-$97M-65.5% margin

EPS (Diluted)

$-4.02

Cash Flow

Operating Cash Flow

-$70M

Free Cash Flow

-$71M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$214M

Total Liabilities

$194M

Stockholders' Equity

$20M

Cash & Equivalents

$166M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$148M	$184M	-19.6%
Gross Profit	$148M	$184M	-19.5%
Operating Income	-$93M	-$205M	+54.5%
Net Income	-$97M	-$202M	+51.9%